I Sverige finns idag bara en aktiv studie för Mesotheliom-behandling
Därför redovisas även alla andra länders studier inom Mesotheliom eller angränsande tumörtyper
SVERIGE:
1 Recruiting
Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma; Lung Cancer
Interventions: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
Andra länders studier:
1 Completed
An Open-Label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: ZD1839
2 Completed
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: pemetrexed; Drug: cisplatin
3 Recruiting
Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
Conditions: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
4 Active, not recruiting
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Condition: Malignant Mesothelioma
Interventions: Drug: doxorubicin hydrochloride; Drug: ranpirnase
5 Recruiting
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Milataxel
6 Terminated
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Vinorelbine; Drug: Vandetanib
7 Recruiting
Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma; Lung Cancer
Interventions: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
8 Completed
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Pemetrexed; Drug: Gemcitabine
9 Active, not recruiting
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: NGR-hTNF
10 Completed
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Pemetrexed
11 Completed
Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: pemetrexed; Drug: cisplatin
12 Recruiting
An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
13 Completed
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Conditions: Carcinoma, Non-Small-Cell Lung; Mesothelioma
Intervention: Drug: LBH589
14 Recruiting
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
15 Completed
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Conditions: Pancreatic Cancer; Mesothelioma; Ovarian Cancer; Non-Small Cell Lung Cancer
Intervention: Drug: MORAb-009
16 Completed
Has Results
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Conditions: Non-small Cell Lung Cancer; Mesothelioma; Lung Neoplasms
Intervention: Drug: pemetrexed
17 Completed
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesotherioma
Interventions: Drug: Pemetrexed; Drug: Cisplatin
18 Approved for marketing
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Condition: Mesothelioma
Interventions: Drug: Pemetrexed; Drug: Cisplatin
19 Terminated
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Conditions: Malignant Epithelial Mesothelioma; Adenocarcinoma of the Pancreas; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma of the Ovaries
Intervention: Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
20 Completed
Has Results
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Condition: Pleural Neoplasms
Interventions: Drug: pemetrexed; Drug: cisplatin
21 Recruiting
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: everolimus
22 Active, not recruiting
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Cisplatin; Drug: Imatinib Mesylate; Drug: Pemetrexed
23 Recruiting
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma
Interventions: Drug: Pemetrexed; Drug: Cisplatin
24 Withdrawn
CryoSpray Ablation(tm)Thoracic Patient Registry
Conditions: Lung Cancer; Emphysema; Chronic Bronchitis; COPD; Asthma; Sarcoidosis; Mesothelioma
Intervention:
25 Recruiting
Dasatinib in Resectable Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Dasatinib
26 Recruiting
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy
27 Active, not recruiting
Sorafenib in Previously Treated Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Sorafenib
28 Withdrawn
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin
29 Not yet recruiting
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
Condition: Cancer
Intervention: Drug: Cetuximab (Erbitux)
30 Recruiting
ChemoFx® PRO – A Post-Market Data Collection Study
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
31 Terminated
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
Conditions: Lung Cancer; Mesothelioma; Malignant Airway Obstruction
Intervention: Device: CryoSpray Ablation (TM) System
32 Recruiting
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
33 Completed
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Conditions: Mesothelioma; Non-small Cell Lung Cancer; Neoplasms
Intervention: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
34 Active, not recruiting
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
35 Recruiting
Gene Therapy for Pleural Malignancies
Conditions: Pleural Mesothelioma; Metastatic Pleural Effusions
Intervention: Genetic: BG00001 (adenoviral-mediated interferon-beta)
36 Completed
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Conditions: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention:Biological: PSMA/PRAME